| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab090883-10μl |
10μl |
现货  |
| |
| Ab090883-50μl |
50μL |
现货 |
| |
| Ab090883-100μl |
100μL |
期货 |
| |
| Ab090883-1ml |
1ml |
期货 |
|
| 产品名称 | Recombinant BCRP/ABCG2 Antibody |
|---|---|
| 别名 | ATP结合盒转运蛋白G2抗体 | ATP结合盒转运蛋白G2单克隆抗体 | ATP结合盒转运蛋白G2重组单克隆抗体 | BCRP抗体 | BCRP单克隆抗体 | BCRP重组单克隆抗体 | ABCG2抗体 | ABCG2单克隆抗体 | ABCG2重组单克隆抗体 |
| 英文别名 | ATP-binding cassette sub-family G member 2 | Breast cancer resistance protein | CDw338 | EC 7.6.2.2 | Mitoxantrone resistance-associated protein | Placenta-specific ATP-binding cassette transporter | Urate exporter | ABC transporter antibody | ABC15 antib |
| 规格或纯度 | 重组, ExactAb™, 已验证, 见COA |
| 生化机理 | Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. May be involved in brain-to-blood efflux. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. When overexpressed, the transfected cells become resistant to mitoxantrone, daunorubicin and doxorubicin, display diminished intracellular accumulation of daunorubicin, and manifest an ATP-dependent increase in the efflux of rhodamine 123. |
| 宿主种属 | 兔(Rabbit) |
| 特异性 | ABCG2 |
| 种属反应性 | 人(Human) |
| 预测反应种属 | 恒河猴(Rhesus Macaque) |
| 免疫原 | A synthetic peptide derived from human BCRP/ABCG2 (AA 150-200). |
| 阳性对照 | WB: HEK293, HeLa, Jurkat, Hep G2 and MCF7 cell lysates. |
| 偶联 | Unconjugated |
| 克隆类型 | 重组抗体 |
|---|---|
| Format | Whole IgG |
| 亚型 | Rabbit IgG |
| 轻链亚型 | kappa |
| SDS-PAGE | 150kDa |
| 纯化方法 | Protein A purified |
| 物理外观 | Liquid |
| 储存缓冲液 | 10mM PBS, 150mM NaCl, 50% Glycerol, 0.05% BSA, 0.02% Sodium azide, pH 7.4 |
| 防腐剂 | 0.02% Sodium azide |
| 浓度 | 见COA |
| 储存温度 | -20°C储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 短期储存2-8℃（1-2周）；长期储存-20℃（24个月）；收货后建议分装，避免反复冻融。 |
| 分子类型 | 抗体 |
Recombinant BCRP/ABCG2 Antibody (Ab090883) - Western Blot
All lanes: Recombinant BCRP/ABCG2 Antibody (Ab090883) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution
Predicted band size: 72 kDa
Observed band size: 75 kDa
Exposure time: 30.0 s
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 应用名称 | 稀释比例 |
|---|---|
| WB | 1/500-1/2000 |
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
 ZJ24F0708380 |
分析证书 | 24-07-17 | Ab090883 |
| ZJ24F0708379 |
分析证书 | 24-07-17 | Ab090883 |
| 1. Rajendra R, Gounder MK, Saleem A, Schellens JH, Ross DD, Bates SE, Sinko P, Rubin EH.. (2003) Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.. Cancer Res, 63 (1): (3228-3233). [PMID:12810652] |
| 2. Janvilisri T, Venter H, Shahi S, Reuter G, Balakrishnan L, van Veen HW.. (2003) Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis.. J Biol Chem, 278 (1): (20645-20651). [PMID:12668685] [10.1074/jbc.m301358200] |
| 3. Nakanishi T, Karp JE, Tan M, Doyle LA, Peters T, Yang W, Wei D, Ross DD.. (2003) Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients.. Clin Cancer Res, 9 (1): (3320-3328). [PMID:12960118] |
| 4. Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD.. (2003) Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.. Cancer Res, 63 (1): (4048-4054). [PMID:12874005] |
| 5. Komatani H, Kotani H, Hara Y, Nakagawa R, Matsumoto M, Arakawa H, Nishimura S.. (2001) Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.. Cancer Res, 61 (1): (2827-2832). [PMID:11306452] |
| 6. Mitomo H, Kato R, Ito A, Kasamatsu S, Ikegami Y, Kii I, Kudo A, Kobatake E, Sumino Y, Ishikawa T.. (2003) A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport.. Biochem J, 373 (1): (767-774). [PMID:12741957] [10.1042/bj20030150] |
| 7. Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S.. (2004) Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.. Int J Cancer, 108 (1): (146-151). [PMID:14618629] [10.1002/ijc.11528] |
| 8. Miwa M, Tsukahara S, Ishikawa E, Asada S, Imai Y, Sugimoto Y.. (2003) Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.. Int J Cancer, 107 (1): (757-763). [PMID:14566825] [10.1002/ijc.11484] |
| 9. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y.. (2003) ABCG2 transports sulfated conjugates of steroids and xenobiotics.. J Biol Chem, 278 (1): (22644-22649). [PMID:12682043] [10.1074/jbc.m212399200] |
| 10. International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V et al.. (2010) Membrane transporters in drug development.. Nat Rev Drug Discov, 9 (3): (215-36). [PMID:20190787] |
| 11. Estrada AA, Chan BK, Baker-Glenn C, Beresford A, Burdick DJ, Chambers M, Chen H, Dominguez SL, Dotson J, Drummond J et al.. (2014) Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.. J Med Chem, 57 (3): (921-36). [PMID:24354345] |
| 12. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells.. Proc Natl Acad Sci USA, 95 (26): (15665-70). [PMID:9861027] |
| 13. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T et al.. (1999) Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.. Cancer Res, 59 (1): (8-13). [PMID:9892175] |
| 14. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. (1998) A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.. Cancer Res, 58 (23): (5337-9). [PMID:9850061] |
| 15. Taylor NMI, Manolaridis I, Jackson SM, Kowal J, Stahlberg H, Locher KP. (2017) Structure of the human multidrug transporter ABCG2.. Nature, 546 (7659): (504-509). [PMID:28554189] |
| 16. Xu R, Wang K, Rizzi JP, Huang H, Grina JA, Schlachter ST, Wang B, Wehn PM, Yang H, Dixon DD et al.. (2019) 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma.. J Med Chem, 62 (15): (6876-6893). [PMID:31282155] |
| 17. Hansen JD, Correa M, Alexander M, Nagy M, Huang D, Sapienza J, Lu G, LeBrun LA, Cathers BE, Zhang W et al.. (2021) CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia.. J Med Chem, 64 (4): (1835-1843). [PMID:33591756] |
| 18. Gerstenberger BS, Ambler C, Arnold EP, Banker ME, Brown MF, Clark JD, Dermenci A, Dowty ME, Fensome A, Fish S et al.. (2020) Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.. J Med Chem, 63 (22): (13561-13577). [PMID:32787094] |
| 19. Koralewski R, Dymek B, Mazur M, Sklepkiewicz P, Olejniczak S, Czestkowski W, Matyszewski K, Andryianau G, Niedziejko P, Kowalski M et al.. (2020) Discovery of OATD-01, a First-in-Class Chitinase Inhibitor as Potential New Therapeutics for Idiopathic Pulmonary Fibrosis.. J Med Chem, 63 (24): (15527-15540). [PMID:33078933] |
| 20. Wang H, Ren B, Liu Y, Jiang B, Guo Y, Wei M, Luo L, Kuang X, Qiu M, Lv L et al.. (2020) Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.. J Med Chem, 63 (24): (15541-15563). [PMID:33264017] |
| 21. Hirotsugu Kobuchi,Koko Moriya,Tetsuya Ogino,Hirofumi Fujita,Keiji Inoue,Taro Shuin,Tatsuji Yasuda,Kozo Utsumi,Toshihiko Utsumi. (2012-11-29) Mitochondrial localization of ABC transporter ABCG2 and its function in 5-aminolevulinic acid-mediated protoporphyrin IX accumulation.. PloS one, 7 ((11)): (e50082-e50082). [PMID:23189181] |
| 22. John T Szilagyi,Anna M Vetrano,Jeffrey D Laskin,Lauren M Aleksunes. (2017-06-19) Localization of the placental BCRP/ABCG2 transporter to lipid rafts: Role for cholesterol in mediating efflux activity.. Placenta, 55 (29-36). [PMID:28623970] |
| 23. Bauer F, Kuntner C, Bankstahl JP, Wanek T, Bankstahl M, Stanek J, Mairinger S, Dörner B, Löscher W, Müller M, Erker T, Langer O.. (2010) Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.. Bioorg Med Chem, 18 (15): (5489-5497). [PMID:20621487] [10.1016/j.bmc.2010.06.057] |
| 24. Versiani MA, Diyabalanage T, Ratnayake R, Henrich CJ, Bates SE, McMahon JB, Gustafson KR.. (2011) Flavonoids from eight tropical plant species that inhibit the multidrug resistance transporter ABCG2.. J Nat Prod, 74 (2): (262-266). [PMID:21275386] [10.1021/np100797y] |
| 25. Valdameri G, Gauthier C, Terreux R, Kachadourian R, Day BJ, Winnischofer SM, Rocha ME, Frachet V, Ronot X, Di Pietro A, Boumendjel A.. (2012) Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity.. J Med Chem, 55 (7): (3193-3200). [PMID:22449016] [10.1021/jm2016528] |
| 26. Gedeon C, Behravan J, Koren G, Piquette-Miller M.. (2006) Transport of glyburide by placental ABC transporters: implications in fetal drug exposure.. Placenta, 27 (1): (1096-1102). [PMID:16460798] [10.1016/j.placenta.2005.11.012] |
| 27. Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K.. (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.. Blood, 104 (1): (2940-2942). [PMID:15251980] [10.1182/blood-2004-04-1398] |
| 28. Minderman H, O'Loughlin KL, Pendyala L, Baer MR.. (2004) VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.. Clin Cancer Res, 10 (1): (1826-1834). [PMID:15014037] [10.1158/1078-0432.ccr-0914-3] |
| 29. Yoshikawa M, Ikegami Y, Hayasaka S, Ishii K, Ito A, Sano K, Suzuki T, Togawa T, Yoshida H, Soda H, Oka M, Kohno S, Sawada S, Ishikawa T, Tanabe S.. (2004) Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.. Int J Cancer, 110 (1): (921-927). [PMID:15170677] [10.1002/ijc.20216] |
| 30. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P.. (2004) Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.. Cancer Res, 64 (1): (2333-2337). [PMID:15059881] [10.1158/0008-5472.can-03-3344] |
| 31. Jabor Gozzi G, Bouaziz Z, Winter E, Daflon-Yunes N, Aichele D, Nacereddine A, Marminon C, Valdameri G, Zeinyeh W, Bollacke A, Guillon J, Lacoudre A, Pinaud N, Cadena SM, Jose J, Le Borgne M, Di Pietro A.. (2015) Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.. J Med Chem, 58 (1): (265-277). [PMID:25272055] [10.1021/jm500943z] |
| 32. Fu J, Tjandra M, Becker C, Bednarczyk D, Capparelli M, Elling R, Hanna I, Fujimoto R, Furegati M, Karur S, Kasprzyk T, Knapp M, Leung K, Li X, Lu P, Mergo W, Miault C, Ng S, Parker D, Peng Y, Roggo S, Rivkin A, Simmons RL, Wang M, Wiedmann B, Weiss AH, Xiao L, Xie L, Xu W, Yifru A, Yang S, Zhou B, Sweeney ZK.. (2014) Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.. J Med Chem, 57 (20): (8503-8516). [PMID:25310383] [10.1021/jm500862r] |
| 33. Ai Y, Kang F, Huang Z, Xue X, Lai Y, Peng S, Tian J, Zhang Y.. (2015) Synthesis of CDDO-amino acid-nitric oxide donor trihybrids as potential antitumor agents against both drug-sensitive and drug-resistant colon cancer.. J Med Chem, 58 (5): (2452-2464). [PMID:25675144] [10.1021/jm5019302] |
| 34. Yang Z, Zhu W, Gao S, Yin T, Jiang W, Hu M.. (2012) Breast cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein.. Drug Metab Dispos, 40 (10): (1883-1893). [PMID:22736306] [10.1124/dmd.111.043901] |
| 35. Wittgen HG, van den Heuvel JJ, van den Broek PH, Siissalo S, Groothuis GM, de Graaf IA, Koenderink JB, Russel FG.. (2012) Transport of the coumarin metabolite 7-hydroxycoumarin glucuronide is mediated via multidrug resistance-associated proteins 3 and 4.. Drug Metab Dispos, 40 (6): (1076-1079). [PMID:22415933] [10.1124/dmd.111.044438] |
| 36. Zhang D, He K, Herbst JJ, Kolb J, Shou W, Wang L, Balimane PV, Han YH, Gan J, Frost CE, Humphreys WG.. (2013) Characterization of efflux transporters involved in distribution and disposition of apixaban.. Drug Metab Dispos, 41 (4): (827-835). [PMID:23382458] [10.1124/dmd.112.050260] |
| 37. Poller B, Iusuf D, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.. (2011) Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.. Drug Metab Dispos, 39 (5): (729-735). [PMID:21282407] [10.1124/dmd.110.037317] |
| 38. Gao C, Zhang H, Guo Z, You T, Chen X, Zhong D.. (2012) Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.. Drug Metab Dispos, 40 (10): (2009-2020). [PMID:22822035] [10.1124/dmd.112.047183] |
| 39. Ishiguro N, Shimizu H, Kishimoto W, Ebner T, Schaefer O.. (2013) Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods.. Drug Metab Dispos, 41 (1): (149-158). [PMID:23073734] [10.1124/dmd.112.048470] |
| 40. Gujarati NA, Zeng L, Gupta P, Chen ZS, Korlipara VL.. (2017) Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors.. Bioorg Med Chem Lett, 27 (20): (4698-4704). [PMID:28916341] [10.1016/j.bmcl.2017.09.009] |
| 41. Crosignani S, Bingham P, Bottemanne P, Cannelle H, Cauwenberghs S, Cordonnier M, Dalvie D, Deroose F, Feng JL, Gomes B, Greasley S, Kaiser SE, Kraus M, Négrerie M, Maegley K, Miller N, Murray BW, Schneider M, Soloweij J, Stewart AE, Tumang J, Torti VR, Van Den Eynde B, Wythes M.. (2017) Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate.. J Med Chem, 60 (23): (9617-9629). [PMID:29111717] [10.1021/acs.jmedchem.7b00974] |
| 42. Krapf MK, Gallus J, Wiese M.. (2017) Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).. Eur J Med Chem, 139 (587-611). [PMID:28841513] [10.1016/j.ejmech.2017.08.020] |
| 43. Buchler I, Akuma D, Au V, Carr G, de León P, DePasquale M, Ernst G, Huang Y, Kimos M, Kolobova A, Poslusney M, Wei H, Swinnen D, Montel F, Moureau F, Jigorel E, Schulze MED, Wood M, Barrow JC.. (2018) Optimization of 8-Hydroxyquinolines as Inhibitors of Catechol O-Methyltransferase.. J Med Chem, 61 (21): (9647-9665). [PMID:30272964] [10.1021/acs.jmedchem.8b01126] |
| 44. Wong ILK, Zhu X, Chan KF, Law MC, Lo AMY, Hu X, Chow LMC, Chan TH.. (2018) Discovery of Novel Flavonoid Dimers To Reverse Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediated Drug Resistance in Cancers Using a High Throughput Platform with "Click Chemistry".. J Med Chem, 61 (22): (9931-9951). [PMID:30351934] [10.1021/acs.jmedchem.8b00834] |
| 45. Zhu X, Wong ILK, Chan KF, Cui J, Law MC, Chong TC, Hu X, Chow LMC, Chan TH.. (2019) Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.. J Med Chem, 62 (18): (8578-8608). [PMID:31465686] [10.1021/acs.jmedchem.9b00963] |
| 46. Chatzopoulou M, Claridge TDW, Davies KE, Davies SG, Elsey DJ, Emer E, Fletcher AM, Harriman S, Robinson N, Rowley JA, Russell AJ, Tinsley JM, Weaver R, Wilkinson IVL, Willis NJ, Wilson FX, Wynne GM.. (2020) Isolation, Structural Identification, Synthesis, and Pharmacological Profiling of 1,2-trans-Dihydro-1,2-diol Metabolites of the Utrophin Modulator Ezutromid.. J Med Chem, 63 (5): (2547-2556). [PMID:31599580] [10.1021/acs.jmedchem.9b01547] |
| 47. Silbermann K, Shah CP, Sahu NU, Juvale K, Stefan SM, Kharkar PS, Wiese M.. (2019) Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2.. Eur J Med Chem, 164 (193-213). [PMID:30594677] [10.1016/j.ejmech.2018.12.019] |
| 48. Wu CP, Lusvarghi S, Hsiao SH, Liu TC, Li YQ, Huang YH, Hung TH, Ambudkar SV.. (2020) Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.. J Nat Prod, 83 (5): (1461-1472). [PMID:32347726] [10.1021/acs.jnatprod.9b01022] |
| 49. Silbermann K,Li J,Namasivayam V,Stefan SM,Wiese M. (2021) Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site.. Eur J Med Chem, 212 (113045-113045). [PMID:33454462] [10.1016/j.ejmech.2020.113045] |
| 50. Guragossian N, Belhani B, Moreno A, Nunes MT, Gonzalez-Lobato L, Marminon C, Berthier L, Rocio Andrade Pires AD, Özvegy-Laczka C, Sarkadi B, Terreux R, Bouaziz Z, Berredjem M, Jose J, Di Pietro A, Falson P, Le Borgne M.. (2021) Uncompetitive nanomolar dimeric indenoindole inhibitors of the human breast cancer resistance pump ABCG2.. Eur J Med Chem, 211 (113017-113017). [PMID:33223263] [10.1016/j.ejmech.2020.113017] |
| 51. Kumar S, Jaipuri FA, Waldo JP, Potturi H, Marcinowicz A, Adams J, Van Allen C, Zhuang H, Vahanian N, Link C, Brincks EL, Mautino MR.. (2020) Discovery of indoximod prodrugs and characterization of clinical candidate NLG802.. Eur J Med Chem, 198 (112373-112373). [PMID:32422549] [10.1016/j.ejmech.2020.112373] |
| 52. Zhou, S S and 10 more authors.. (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype.. Nature medicine, [PMID:11533706] |
| 53. Iida, Aritoshi A and 8 more authors.. (2002) Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8.. Journal of human genetics, [PMID:12111378] |
| 54. Zhang, Wandong W and 5 more authors.. (2003) The expression and functional characterization of ABCG2 in brain endothelial cells and vessels.. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, [PMID:12958161] |
| 55. Xu, Junkang J, Liu, Yang Y, Yang, Youyun Y, Bates, Susan S and Zhang, Jian-Ting JT.. (2004) Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2.. The Journal of biological chemistry, (7): [PMID:15001581] |
| 56. Itoda, Masaya M and 10 more authors.. (2003) Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan.. Drug metabolism and pharmacokinetics, [PMID:15618737] |
| 57. Ozvegy-Laczka, Csilla C, Köblös, Gabriella G, Sarkadi, Balázs B and Váradi, András A.. (2005) Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.. Biochimica et biophysica acta, (1): [PMID:15670731] |
| 58. Henriksen, Ulla U, Gether, Ulrik U and Litman, Thomas T.. (2005) Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.. Journal of cell science, (1): [PMID:15769853] |
| 59. Diop, Ndeye K NK and Hrycyna, Christine A CA.. (2005) N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane.. Biochemistry, (12): [PMID:15807535] |
| 60. Hillier, Ladeana W LW and 121 more authors.. (2005) Generation and annotation of the DNA sequences of human chromosomes 2 and 4.. Nature, (7): [PMID:15815621] |
| 61. Morisaki, Kuniaki K and 7 more authors.. (2005) Single nucleotide polymorphisms modify the transporter activity of ABCG2.. Cancer chemotherapy and pharmacology, [PMID:15838659] |
| 62. Wakabayashi, Kanako K and 6 more authors.. (2007) Intramolecular disulfide bond is a critical check point determining degradative fates of ATP-binding cassette (ABC) transporter ABCG2 protein.. The Journal of biological chemistry, (21): [PMID:17686774] |
| 63. Xie, Yingqiu Y and 11 more authors.. (2008) The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells.. The Journal of biological chemistry, (8): [PMID:18056989] |
| 64. Dehghan, Abbas A and 14 more authors.. (2008) Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study.. Lancet (London, England), (6): [PMID:18834626] |
| 65. Woodward, Owen M OM and 5 more authors.. (2009) Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout.. Proceedings of the National Academy of Sciences of the United States of America, (23): [PMID:19506252] |
| 66. Henrich, Curtis J and 8 more authors.. (2009) Botryllamides: natural product inhibitors of ABCG2.. ACS chemical biology, (21): [PMID:19555120] |
| 67. Takabe, Kazuaki K and 9 more authors.. (2010) Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2.. The Journal of biological chemistry, (2): [PMID:20110355] |
| 68. Brechbuhl, Heather M HM and 5 more authors.. (2010) Glutathione transport is a unique function of the ATP-binding cassette protein ABCG2.. The Journal of biological chemistry, (28): [PMID:20332504] |
| 69. Matsuo, Hirotaka H and 33 more authors.. (2009) Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population.. Science translational medicine, (4): [PMID:20368174] |
| 70. Desuzinges-Mandon, Elodie E and 5 more authors.. (2010) ABCG2 transports and transfers heme to albumin through its large extracellular loop.. The Journal of biological chemistry, (22): [PMID:20705604] |
| 71. Nakayama, Akiyoshi A and 10 more authors.. (2011) ABCG2 is a high-capacity urate transporter and its genetic impairment increases serum uric acid levels in humans.. Nucleosides, nucleotides & nucleic acids, [PMID:22132962] |
| 72. Saison, Carole C and 11 more authors.. (2012) Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior.. Nature genetics, (15): [PMID:22246505] |
| 73. Zelinski, Teresa T, Coghlan, Gail G, Liu, Xiao-Qing XQ and Reid, Marion E ME.. (2012) ABCG2 null alleles define the Jr(a-) blood group phenotype.. Nature genetics, (15): [PMID:22246507] |
| 74. Manolaridis, Ioannis I and 5 more authors.. (2018) Cryo-EM structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states.. Nature, [PMID:30405239] |
| 75. Toyoda, Yu Y and 11 more authors.. (2019) Functional Characterization of Clinically-Relevant Rare Variants in ABCG2 Identified in a Gout and Hyperuricemia Cohort.. Cells, (18): [PMID:31003562] |
| 76. Zámbó, Boglárka B and 8 more authors.. (2019) Cellular expression and function of naturally occurring variants of the human ABCG2 multidrug transporter.. Cellular and molecular life sciences : CMLS, (28): [PMID:31254042] |
首页
400-620-6333
